Covered recipient · General Payments record
ANIL GUPTA
Allopathic & Osteopathic Physicians Allergy & Immunology
General Payments · PY2018–2024
$2,398.34
- Reported across 96 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $256.16 | 13 |
| Education | $99.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $99.99 | 1 |
| GENZYME CORPORATION | $74.04 | 4 |
| Novo Nordisk AS | $44.67 | 2 |
| Amgen Inc. | $37.19 | 2 |
| Lilly USA, LLC | $25.71 | 1 |
| Acerta Pharma LLC | $21.17 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.56 | 1 |
| BioCryst US Sales Co., LLC | $17.35 | 1 |
| PFIZER INC. | $15.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $14.34 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111591088 | CMS |
| Amgen Inc. | $22.85 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111591090 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.17 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104544958 | CMS |
| BioCryst US Sales Co., LLC | $17.35 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117479588 | CMS |
| GENZYME CORPORATION | $22.55 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139907677 | CMS |
| GENZYME CORPORATION | $18.27 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139907691 | CMS |
| GENZYME CORPORATION | $18.98 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139907743 | CMS |
| GENZYME CORPORATION | $14.24 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139907757 | CMS |
| Lilly USA, LLC | $25.71 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136042026 | CMS |
| Novartis Pharmaceuticals Corporation | $20.56 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086960585 | CMS |
| Novo Nordisk Inc | $22.64 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097336638 | CMS |
| Novo Nordisk Inc | $22.03 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096757488 | CMS |
| PFIZER INC. | $15.47 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131704690 | CMS |
| SANOFI-AVENTIS U.S. LLC | $99.99 | 06/26/2024 | Education | Undisputed | 01/23/2026 | 1139907721 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.